Scancell Is A Uk Based Clinical Stage Biopharmaceutical Company Focused On Developing Immuno Oncology Therapies For Cancers With Significant Unmet Needsfounded In 1996 And Headquartered At The Oxford Science Parkscancell Aims To Translate Innovative Science Into Effective Treatments That Provide Durable Patient Responses While Ensuring Safety The Company Utilizes Four Proprietary Technology Platformsmoditopewhich Activates Cd4T Cells To Recognize Tumorsimmunobodya Dna Based Vaccine Platform Targeting Solid Tumorsglymabwhich Enhances Antibody Dependent Cellular Cytotoxicityand Avidimabengineered Antibodies For Improved Tumor Targetingscancell S Product Pipeline Includes Several Candidates In Various Stages Of Clinical Trialssuch As Modi 1 For Triple Negative Breast Cancerscib1 For Metastatic Melanomaand Covid 19 Vaccine Candidates Under The Covidity Programthe Company Collaborates With The Nhs Cancer Vaccine Launch Pad To Expedite Access For Melanoma Patients
No conferences found for this company.
| Company Name | Scancell Ltd |
| Country |
United Kingdom
|
| Address | N/A |
| Telephone | N/A |
| N/A |
